Dicerna Pharmaceuticals reported $239.3M in Current Liabilities for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acceleron Pharma XLRN:US $ 57.37M 2.11M
Alnylam Pharmaceuticals ALNY:US $ 610.66M 56.01M
Amgen AMGN:US $ 14842M 257M
Arrowhead Research ARWR:US $ 146.54M 48.9M
Biogen BIIB:US $ 4211.6M 864.4M
Bluebird Bio BLUE:US $ 266.56M 18.79M
Dicerna Pharmaceuticals DRNA:US $ 239.3M 31.64M
Exelixis EXEL:US $ 269.51M 14.18M
Gilead Sciences GILD:US $ 10245M 31M
GlaxoSmithKline GSK:LN 22417M 1030M
Immunogen IMGN:US $ 111.78M 8.53M
Intrexon XON:US $ 28.99M 0.12M
IONIS PHARMACEUT IONS:US $ 218M 75.82M
Karyopharm Therapeutics KPTI:US $ 68.87M 10.74M
Macrogenics MGNX:US $ 68.86M 1.06M
Mirati Therapeutics MRTX:US $ 122.08M 58.79M
Regeneron Pharmaceuticals REGN:US $ 3714.8M 17.6M
Ultragenyx Pharmaceutical RARE:US $ 135.93M 8.87M